Research Article
Levels of Circulating Microparticles in Lung Cancer Patients and Possible Prognostic Value
Table 1
Baseline characteristics of study patients and normal control subjects.
| | Variable | Study patients (n = 130) | Normal control (n = 30) | P |
| | Age (years) | 64.34 ± 12.12 | 64.01 ± 8.56 | 0.863 | | Male gender | 55.5% (71) | 50% (15) | 0.824 | | Body mass index (kg/m2) | 22.64 ± 3.99 | 23.56 ± 3.09 | 0.169 | | Stage I | 2.3% (3) | — | | | Stage II | 2.3% (3) | — | | | Stage IIIa | 27.7% (17) | — | | | Stage IIIb | 14.6% (19) | — | | | Stage IV | 67.7% (88) | — | | | Surgical intervention for LC | 0% (0) | — | | | History of smoking | 45.4% (59) | — | | | Hypertension | 18.5% (24) | — | | | Hypercholesterolemia | 16.4% (21) | — | | | Diabetes mellitus | 9.2% (12) | — | | | RBC count (×106/dL) | 4.29 ± 1.28 | 4.89 ± 0.55 | 0.001 | | WBC count (×103/dL) | 7.43 ± 2.99 | 5.88 ± 1.28 | 0.001 | | Platelet count (×104/dL) | 23.78 ± 9.84 | 22.45 ± 4.07 | 0.185 | | Creatinine (mg/dL) | 1.02 ± 0.54 | 0.88 ± 0.19 | 0.167 | | AST (IU/L) | 98.98 ± 683.77 | 27.44 ± 11.07 | <0.001 | | ALT (IU/L) | 51.22 ± 223.41 | 30.56 ± 16.83 | <0.001 | | Ac sugar (mg/dL) | 131.51 ± 62.9 | 105.27 ± 5.47 | 0.001 | | CD31+ CD42b− AN-V+ (counts/mL)† | 783 (306–2014) | 457 (189–1127) | 0.012 | | CD31+ CD42b− AN-V− (counts/mL)† | 6969 (2745–15206) | 5851 (3619–10105) | 0.046 | | CD31+ CD42b+ AN-V+ (counts/mL)† | 15669 (6020–50968) | 9817 (3867–38418) | 0.001 | | CD31+ CD42b+ AN-V− (counts/mL)† | 25069 (12224–51123) | 14923 (8293–20839) | 0.001 |
|
|
Data are expressed as mean ± SD or % (number).
LC: lung cancer; BC: right blood cell count; WBC: white blood cell count; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
†CD31+ CD42b− AN-V+: endothelial-derived apoptotic microparticle (MP); CD31+ CD42b− AN-V−: endothelial-derived activated MP; CD31+ CD42b+ AN-V+: platelet-derived apoptotic MP; CD31+ CD42b+ AN-V−: platelet-derived activated MP.
|
